Prediction of All-Cause Mortality Based on the Direct Measurement of Intrathoracic Impedance
Overview
Affiliations
Background: Intrathoracic impedance-derived OptiVol fluid index calculated using implanted devices has been shown to predict mortality; direct measurements of impedance have not been examined. We hypothesized that baseline measured impedance predicts all-cause mortality; changes in measured impedance result in a change in the predicted mortality; and the prognostic value of measured impedance is additive to the calculated OptiVol fluid index.
Methods And Results: A retrospective analysis of 146,238 patients within the Medtronic CareLink database with implanted devices was performed. Baseline measured impedance was determined using daily values averaged from month 6 to 9 after implant and were used to divide patients into tertiles: group L = low impedance, ≤ 65 ohms; group M = medium impedance, 66 to 72 ohms; group H = high impedance, ≥ 73 ohms. Change in measured impedance was determined from values averaged from month 9 to 12 post implant compared with the 6- to 9-month values. OptiVol fluid index was calculated using published methods. All-cause mortality was assessed beginning 9 months post implant; changes in mortality was assessed beginning 12 months post implant. Baseline measured impedance predicted all-cause mortality; 5-year mortality for group L was 41%, M was 29%, and H was 25%, P < 0.001 among all groups. Changes in measured impedance resulted in a change in the predicted mortality; the prognostic value of measured impedance was additive to the OptiVol fluid index.
Conclusions: Direct measurements of intrathoracic impedance using an implanted device can be used to stratify patients at varying mortality risk.
Heart Failure Management through Telehealth: Expanding Care and Connecting Hearts.
Tedeschi A, Palazzini M, Trimarchi G, Conti N, Di Spigno F, Gentile P J Clin Med. 2024; 13(9).
PMID: 38731120 PMC: 11084728. DOI: 10.3390/jcm13092592.
Remote monitoring data from cardiac implantable electronic devices predicts all-cause mortality.
Ahmed F, Sammut-Powell C, Kwok C, Tay T, Motwani M, Martin G Europace. 2021; 24(2):245-255.
PMID: 34601572 PMC: 8824524. DOI: 10.1093/europace/euab160.
Home Management of Heart Failure and Arrhythmias in Patients with Cardiac Devices during Pandemic.
Matteucci A, Bonanni M, Centioni M, Zanin F, Geuna F, Massaro G J Clin Med. 2021; 10(8).
PMID: 33920350 PMC: 8069073. DOI: 10.3390/jcm10081618.
Zile M, Costanzo M, Ippolito E, Zhang Y, Stapleton R, Sadhu A ESC Heart Fail. 2021; 8(2):849-860.
PMID: 33527654 PMC: 8006696. DOI: 10.1002/ehf2.13231.
Zile M, Sharma V, Baicu C, Koehler J, Tang A ESC Heart Fail. 2020; 7(5):3040-3048.
PMID: 32790059 PMC: 7524260. DOI: 10.1002/ehf2.12930.